. Archives of Disease in Childhood, 50, 387. Effect of placebo substitution during long-term betamethasone valerate aerosol treatment in asthmatic children. Ten children with severe asthma, who had been well controlled on maintenance betamethasone valerate aerosol for an average of 11 months, were given placebo aerosols without their knowledge. The period of placebo substitution was compared with one 28-day period of betamethasone valerate therapy beforehand, and two 28-day periods afterwards.
since the onset of asthma. Subjective observations are supported by analysis of daily PEFR and symptom scores recorded at home. In terms of every day life, patients are no longer hampered by their symptoms, and are able to attend school regularly and participate normally in all physical activities. The social and emotional deficit which arises from chronic ill-health has in many cases disappeared.
After initial stabilization, the child's treated state often resembles a spontaneous remission, and some parents have questioned the need to continue therapy, and in some cases have discontinued it themselves with adverse effect. The influence of suggestion upon the clinical state in asthma is well known, and we were unable to determine whether the return of symptoms seen on these occasions was due to withdrawal of the drug itself, or to anxiety Frears, Hodgso aroused by stopping a treatment which the patient had come to regard as essential. It became desirable to withdraw therapy in a controlled fashion to show whether individual children required to continue its use. We also hoped to show that this drug does not lead to dependency by discontinuing treatment in some children after a period of prolonged maintenance.
A group of children with previously severe asthma, who had been well controlled on betamethasone valerate therapy, were therefore supplied with placebo aerosols without their knowledge, and their clinical condition during this period was compared with that during active treatment.
Method
Patients. 10 patients receiving long-term betamethasone valerate treatment on a dose-scale ranging from 800 jig daily to 200 jig daily, were selected. These subjects, details of whom are shown in Table I , had a mean age of 9 9 years (range 7-6-12 8 yr), and had used betamethasone valerate for a mean of 11 months (range 6-15 m). All were sufficiently improved in comparison with their pretreatment state to have raised the question of discontinuing prophylactic therapy, and in each case the parents' permission had been obtained to substitute a placebo aerosol at some future unspecified date. All aerosols kept at home were handed in at every outpatient attendance and replaced with new ones to facilitate placebo substitution.
Protocol. Four 28-day periods were included in the trial. During the first period (I) the children continued treatment with long-term betamethasone valerate. Placebo treatment was substituted in the second period (II), using pressurized aerosols identical in appearance and labelling to active aerosols, but containing propellants only. If the patients' clinical state deteriorated during placebo treatment or before the planned period of substitution had been completed, betamethasone valerate was reintroduced in the third period (III) at a dose of 800 pg daily. We have observed that it takes )n, and Friedman several weeks to achieve maximum benefit from this therapy, so a fourth period (IV) was included in the assessment on the assumption that this would represent a return to the optimum clinical state on active therapy.
All children attending our asthma clinic are seen at short notice on request, and parents are asked to get in touch with us on any occasion when they are worried about their child's symptoms. Advice is available at all times. This service is routine and was not particularly emphasized on the occasion when a patient was given a placebo aerosol.
Assessment. Assessment was made of the resting clinical state from daily observations recorded at home, and also by provocation using standardized exercise as a form of stress.
Observations made in the home. The children kept diary cards (Connolly and Godfrey, 1970) , on which were recorded daily symptoms in the form of a score ranging from 0 (no symptoms) to 13 (severe symptoms). 
3LE I
Clinical details of children taking part in the trial
The upper limit of normal for the % fall in PEFR with exercise was taken as 10% (Silverman and Anderson, 1972) and as 22% for the Exercise Lability Index ( K6nig and Godfrey, 1973) . All statistical comparisons in the trial were made by means of the paired 't' test and the level of significance was taken as P <0-05.
Results Fig. 1 shows the individual response of one child taking part in the trial.
Observations made in the home. Symptoms. The duration of the placebo period for each patient is given in Table I . 6 children experienced an exacerbation of symptoms on placebo therapy which became unacceptable in spite of treatment with bronchodilators and night sedation. They asked to be seen before completion of the planned substitution period of 28 days, and active treatment was reintroduced. The remaining 4 children completed the period of placebo treatment, which was extended in 2 cases. 3 of them were then returned to betamethasone valerate therapy because both we and their parents felt they had been worse without it.
Total symptom scores recorded by the 10 children in each period of the trial are shown in Table II . After placebo substitution, one child discontinued active therapy, and one ceased to keep proper records. 8 children thus had readings which could be compared in each period, and the means of these 8 are shown in Fig. 2 .
Analysis of the records shows that symptom scores in the placebo period were higher than in period I (P = 0 01) and period IV (P = 0-01). The decrease in symptoms between period III and period IV is also singificant (0 05 > P > 0 02). There is no difference between the symptoms recorded in periods I and IV.
Changes in PEFR. 9 children used peak flow meters at home, and the averages of daily morning and evening PEFR during the trial are shown in Table III . The mean peak flow values of the 7 children whose readings could be compared throughout the trial are shown in Fig. 2 .
Taking the mean of morning and evening readings in each period, all 9 children had a lower mean PEFR in period II than in period I, though (1966) to have no effect on exercise-induced asthma. Heimlich, Strick, and Busser (1966) found that a 3-day course of prednisone 30 mg daily halved the fall in PEFR after exercise. Though betamethasone valerate therapy has no immediate efect on exercise-induced bronchoconstriction, a comparison of standardized running tests suggested that its long-term use diminishes exercise-induced asthma (Hodgson, McPherson, and Friedman, 1974 exacerbation of asthma is the last thing to return to normal in a remission. Narrowing of the diurnal variation may play a part in the mechanism of long-term improvement.
Two of these 10 children, whose symptoms in the past had been severe, are now sufficiently improved to have discontinued therapy. Case 10 was dependent on long-term ACTH before successful conversion to betamethasone valerate maintenance, which continued for 14 months. He had an exacerbation of symptoms during the placebo period, but his mother found his condition tolerable and preferred to discontinue treatment. Case 8, who had been treated with betamethasone valerate for 10 months, was not markedly worse during the placebo period and was able to discontinue therapy shortly after completion of the trial. We feel that these cases provide some indication that betamethasone valerate maintenance does not lead to long-term dependency.
The results of this trial confirm our opinion that betamethasone valerate is a valuable prophylactic therapy for severe childhood asthma, and must now provide a useful alternative to ACTH or oral steroid maintenance when conventional therapy ceases to be effective. 
